Five things for pharma marketers to know: Thursday, March 15, 2018
The FDA is taking steps towards limiting the amount of nicotine allowed in cigarettes. The government agency said in an advanced notice that it is working towards a guideline “where nicotine levels in cigarettes do not spur or sustain addiction for some portion of potential smokers.” (CNBC).
Alexion Pharmaceuticals said Thursday that an experimental treatment for consumers with rare blood disorders was found not inferior to Soliris, its flagship drug, in tests. The development could help the company keep its hold on the market. (Reuters)
Oregon's governor signed a bill this week that proponents say will lower the cost of drug prices and bring more transparency to the pricing process. The bill requires drugmakers to report R&D, marketing costs, and other info about drugs that receive more than a 10% markup. (OPB)
FDA experts have scheduled a date to weigh in on Eli Lilly's rheumatoid arthritis drug baricitinib. On April 23, government experts will take a second look at the one-time blockbuster hopeful, which was rejected for safety issues last year. (Endpoints News)
Digital medicine: The term is fraught with complexity for even medical experts. MM&M spoke with Akili Labs cofounder Adam Gazzaley about how he defines “digital medicine,” and where the field is positioned in the hype cycle (MM&M)